GlobeNewswire by notified

Transaktioner i henhold til aktietilbagekøbsprogram

Del

SELSKABSMEDDELELSE

A.P. Møller - Mærsk A/S – Transaktioner i henhold til aktietilbagekøbsprogram

Den 5. maj 2021 annoncerede A.P. Møller - Mærsk A/S (“Selskabet”) et aktietilbagekøbsprogram til en værdi af op til DKK 32 mia. (ca. USD 5 mia.), der vil blive opkøbt over en periode på op til to år. Den 2. november 2021 besluttede Selskabet at forøge det nuværende aktietilbagekøbsprogram med yderligere DKK 32 mia. (ca. USD 5 mia.) i løbet af 2024 og 2025, hvilket bringer det samlede program op til i alt DKK 64 mia. (ca. USD 10 mia.). Den 12. august 2022 offentliggjorde Selskabet en forøgelse af aktietilbagekøbsprogrammet op til DKK 84 mia. (ca. USD 6 mia.).                

Som annonceret den 6. november 2023, vil Selskabet i femte fase af programmet, der løber fra 3. november 2023 til 1. maj 2024, købe egne A-aktier og B-aktier for et beløb op til DKK 11 mia. Femte fase af tilbagekøbsprogrammet gennemføres i overensstemmelse med EU Kommissionens forordning nr. 596/2014 af 16. april 2014 (MAR) og EU Kommissionens delegerede forordning 2016/1052 (”Safe Harbour Regulativet”).                                                                             
Under aktietilbagekøbsprogrammet er der i perioden fra 4. december mandag til 8. december fredag foretaget følgende transaktioner:

Antal
A aktier
Gennemsnitlig
købspris A aktier, DKK
Transaktionsværdi,
A aktier, DKK
I alt, seneste meddelelse (marked og A.P. Møller Holding A/S)537.1217.892.870.326
 4 december 202380010.820.82508.656.660
 5 december 202375010.579.66677.934.750
 6 december 202375010.433.17337.824.880
 7 december 202385010.307.55298.761.420
 8 december 202380010.385.71258.308.570
Total 4. -8. december 20233.95041.486.280
Køb fra A.P. Møller Holding A/S*4.18710.502.855743.975.457
Total i femte fase af aktie-tilbagekøbsprogrammet (marked og A.P. Møller Holding A/S)46.247475.685.240
Total under aktietilbagekøbs-
programmet (marked og A.P. Møller Holding A/S)
545.2587.978.332.062
Antal
B aktier
Gennemsnitlig
købspris B aktier, DKK
Transaktionsværdi,
B aktier, DKK
I alt, seneste meddelelse (marked, A.P. Møller Holding A/S og Familiefonden)2.233.58734.128.666.392
 4 december 20233.19210.980.487235.049.715
 5 december 20232.99210.689.054131.981.650
 6 december 20232.99210.561.323531.599.480
 7 december 20233.39110.385.375235.216.807
 8 december 20233.19210.470.338333.421.320
Total 4. -8. december 202315.759167.268.972
Køb fra A.P. Møller Holding A/S*12.63210.614.1955134.078.518
Købt fra Familiefonden*3.98010.614.204042.244.532
Total i femte fase af aktie-tilbagekøbsprogrammet (marked, A.P. Møller Holding A/S og Familiefonden)194.0242.013.988.139
Total under aktietilbagekøbs-
programmet (marked, A.P. Møller Holding A/S og Familiefonden)
2.265.95834.472.258.414

Side 1 af 2

*) I henhold til separate aftaler deltager A.P. Møller Holding A/S og A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (Familiefonden) på pro rata basis i forhold til aktier købt under tilbagekøbsprogrammet.

Efter ovenstående transaktioner ejer Selskabet i alt 286.036 A-aktier og 1.197.959 B-aktier som egne aktier, svarende til 8,45% af aktiekapitalen.

Detaljerede handelsoplysninger er vedhæftet som bilag.

København, 11. december 2023

Kontaktpersoner:

Head of Investor Relations, Stefan Gruber, tlf. +45 5357 1650
Head of Media Relations, Jesper Løv, tlf. +45 6114 1521

Side 2 af 2

Vedhæftede filer

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release

BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab23.2.2024 23:35:31 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will, with the exception of deferred annual cash bonus, be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,013. The restricted stock units will vest on the first ban

Karate Combat 46 to enhance Dubai’s standing as a leading sports tourism destination23.2.2024 20:00:38 CET | Press release

KC46 will be held on Saturday 20 April First professional sports league gamified by a blockchain access token DUBAI, United Arab Emirates, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Karate Combat, the world’s premier full-contact professional striking league, has partnered with Dubai Department of Economy and Tourism (DET) and Dubai Sports Council (DSC) to bring Karate Combat 46 (KC46) to the emirate this spring. Expected to be the league’s biggest event to date, KC46 is collaborating with TOKEN2049 for a Saturday 20 April event. As part of the collaboration KC46 will be part of the official programme of TOKEN2049 Week Dubai, giving conference attendees the opportunity to witness one of the world’s most innovative sports leagues through special tickets and the opportunity to meet event ambassadors at the conference. KC46 will be announced by UFC Hall of Famers Georges St-Pierre (GSP) and Bas Rutten, alongside Mike Majlak, author and co-host of the Impaulsive podcast. Karate Combat is the first

HiddenA line styled icon from Orion Icon Library.Eye